Lundberg Ingrid E
Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
Rheum Dis Clin North Am. 2005 Aug;31(3):535-47, vii-viii. doi: 10.1016/j.rdc.2005.04.005.
The prognosis for patients who have mixed connective tissue disease (MCTD) varies from a benign course to severe progressive disease. In approximately one third of patients the clinical symptoms go into long-term remission and the anti-U1 small nuclear ribonucleoprotein antibodies disappear. One third of patients have a severe, progressive disease course. Persistent morbidity often is attributable to arthritis, easy fatiguability, and dyspnea on exertion. The most severe clinical manifestation is pulmonary hypertension which contributes to premature death in patients who have MCTD. Pulmonary hypertension is associated with proliferative vascular abnormalities that involve small pulmonary vessels, rather than interstitial lung disease.
混合性结缔组织病(MCTD)患者的预后差异较大,从病情良性发展到严重的进行性疾病都有可能。大约三分之一的患者临床症状会长期缓解,抗U1小核糖核蛋白抗体消失。另有三分之一的患者病情严重且呈进行性发展。持续的发病往往归因于关节炎、易疲劳以及劳力性呼吸困难。最严重的临床表现是肺动脉高压,它会导致MCTD患者过早死亡。肺动脉高压与累及小肺血管的增殖性血管异常有关,而非间质性肺病。